Intellia raises ~$194.6M in public offering of 16.7M shares at $10.75; preliminary cash $517.2M as of March 31

Intellia Therapeutics, Inc.

Offered 16,744,187 shares at $10.75/share; underwriters exercised full option for 2,511,628 additional shares; net proceeds ~$194.6M.
Proceeds will advance clinical development and commercial launch prep for lonvoguran ziclumeran (HAE), pipeline R&D, and potential acquisitions.
Preliminary unaudited cash, cash equivalents and marketable securities as of March 31, 2026: ~$517.2M; raised $33.6M from ATM program in Q1.
Company expects combined cash to fund expenses into 2028, excluding potential HAE product revenue, milestone payments, or strategic capital.
Potential FDA approval of lonvoguran ziclumeran for hereditary angioedema anticipated in first half of 2027.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Intellia Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets Inc. valued at approximately $194.6 million (effective 2026-04-28).

Action: entry
Agreement: underwriting
Counterparty: Jefferies LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets Inc.
Value: approximately $194.6 million
Effective: 2026-04-28

Exact text from the filing

On April 28, 2026, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets Inc. (the “Underwriters”), related to a public offering (the “Offering”) of 16,744,187 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) at a price to the public of $10.75 per share.

View on SEC.gov

Browse all material agreements →

Intellia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-197489

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.